Jupiter Neurosciences, Inc. (Ticker: JUNS) is a clinical-stage pharmaceutical company focused on developing treatments for neuro-inflammation, primarily through its lead product candidate, JOTROL, which is based on a resveratrol platform. JOTROL is formulated using a patented micellar technology to enhance the bioavailability of resveratrol, targeting conditions such as Parkinson's Disease, Mucopolysaccharidoses Type 1, Friedreich’s Ataxia, and Mild Cognitive Impairment.

Jupiter Neurosciences is set to list on NASDAQ on October 1, 2024. The company will offer 2.75 million shares at a price of $4.00 per share, aiming to raise $11.0 million. The estimated market capitalization at offer is $131.51 million. The offering is managed by Dominari Securities and Revere Securities. Proceeds will be used to fund a Phase II clinical trial for Parkinson's Disease and to support the company’s expansion into Southeast Asia.